2seventy bio (TSVT) Stock Price, News & Analysis

Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $5.00 to $5.00
• 50-Day Range: $4.96 to $5.00
• 52-Week Range: $2.29 to $5.30
• Volume: N/A
• Average Volume: 642,396 shs
• Market Capitalization: $266.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

TSVT Stock Analysis - Frequently Asked Questions

How have TSVT shares performed this year?

2seventy bio's stock was trading at $2.94 on January 1st, 2025. Since then, TSVT stock has increased by 70.1% and is now trading at $5.00.
View the best growth stocks for 2025 here.

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) issued its quarterly earnings results on Wednesday, May, 7th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.11. The firm earned $22.94 million during the quarter, compared to analysts' expectations of $13.96 million. 2seventy bio had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 207.25%.

Who are 2seventy bio's major shareholders?

2seventy bio's top institutional investors include Goldman Sachs Group Inc. (8.80%), Beryl Capital Management LLC (7.98%), Groupe la Francaise (0.90%) and Charles Schwab Investment Management Inc. (0.79%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, William D Baird III, Nick Leschly, Victoria Eatwell, Jessica Snow, Philip D Gregory, Nicola Heffron, Marcela V Maus and Global Healthcare Master Kynam.
View institutional ownership trends.

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 2seventy bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSVT
• CIK: 1860782
• Web: www.2seventybio.com
• Phone: 339-499-9300
• Fax: N/A
• Employees: 440
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: 0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$217.57 million
• Net Margins: -207.25%
• Pretax Margin: -207.25%
• Return on Equity: -53.65%
• Return on Assets: -23.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.95
• Quick Ratio: 4.95

Sales & Book Value

• Annual Sales: $48.37 million
• Price / Sales: 5.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.04 per share
• Price / Book: 0.99

Miscellaneous

• Outstanding Shares: 53,230,000
• Free Float: 47,874,000
• Market Cap: $266.15 million
• Optionable: Optionable
• Beta: 1.04